Therapeutic implications of the effects of oral hypoglycaemic therapy on the enteroinsular axis in type 2 diabetes.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-004748-30-GB

Enrollment

Registered

2006-02-24

Start date

2006-08-14

Completion date

Unknown

Last updated

2019-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

Product Name: GLP-1 Pharmaceutical Form: Injection* Pharmaceutical form of the placebo: Injection* Route of administration of the placebo: Cutaneous use

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetes - controlled with diet or single oral hypoglycaemic agent. - HbA1C=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Type 2 diabetes - on 2 or more hypoglycaemic agents or on insulin - HbA1C >7.5% Creat>150 Significant cardiac or liver disease. Women of child bearing age (pre-menopausal) including pregnant and breast feeding women

Design outcomes

Primary

Measure	Time frame
Main Objective: Effects of exogenous GLP-1 with or without metformin or nateglinide on plasma DPPIV, GLP-1 and the metabolic response to feeding in subjects with type 2 diabetes. ;Secondary Objective: ;Primary end point(s): Plasma glucose, insulin, C-peptide, glucagon, DPPIV, GLP-1	—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026